SEC Comment Letter for BIOMARIN PHARMACEUTICAL INC (BMRN) (CIK 0001048477) (BMRN) — May 25, 2017
BIOMARIN PHARMACEUTICAL INC (BMRN) (CIK 0001048477)
Date: May 25, 2017 · CIK: 0001048477 · Accession: 0000000000-17-018450
AI Filing Summary & Sentiment
Reasoning
Letter
Mail Stop 4546 May 25, 2017 Via E -mail Mr. Daniel Spiegelman Executive Vice President and Chief Financial Officer BioMarin Pharmaceutical, Inc. 770 Lindaro Street San Rafael, CA 94901
Re: BioMarin Pharmaceutical, Inc. Form 10-K for Fiscal Year Ended December 31, 2016 Filed February 27, 2017 File No. 001 -26727
Dear Mr. Spiegelman :
We have completed our review of your filing s. We remind you that the company and its management are responsible for the accuracy and adequacy of the ir disclosure s, notwithstanding any review, comments, action or absence of action by the staff .
Sincerely,
/s/ Angela M. Connell
Show Raw Text
Mail Stop 4546 May 25, 2017 Via E -mail Mr. Daniel Spiegelman Executive Vice President and Chief Financial Officer BioMarin Pharmaceutical, Inc. 770 Lindaro Street San Rafael, CA 94901 Re: BioMarin Pharmaceutical, Inc. Form 10-K for Fiscal Year Ended December 31, 2016 Filed February 27, 2017 File No. 001 -26727 Dear Mr. Spiegelman : We have completed our review of your filing s. We remind you that the company and its management are responsible for the accuracy and adequacy of the ir disclosure s, notwithstanding any review, comments, action or absence of action by the staff . Sincerely, /s/ Angela M. Connell Angela M. Connell Accounting Branch Chief Office of Healthcare and Insurance